[(1'R,3aR,4S,4'R,5R,6S,7S,7aR)-5,6,7-trihydroxy-1',7',7'-trimethylspiro[3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole-2,2'-bicyclo[2.2.1]heptane]-4-yl] 4-methylbenzenesulfonate | 330995-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(1'R,3aR,4S,4'R,5R,6S,7S,7aR)-5,6,7-trihydroxy-1',7',7'-trimethylspiro[3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole-2,2'-bicyclo[2.2.1]heptane]-4-yl] 4-methylbenzenesulfonate
• CAS: 330995-03-4
• 化学式: C₂₃H₃₂O₈S
• 分子量: 468.568
• InChiKey: YHOZBRAKVJUJMJ-WHXPADPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 [(1'R,3aR,4S,4'R,5R,6S,7S,7aR)-5,6,7-trihydroxy-1',7',7'-trimethylspiro[3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole-2,2'-bicyclo[2.2.1]heptane]-4-yl] 4-methylbenzenesulfonate 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 [(1'R,3aS,4R,4'R,5S,6R,7R,7aR)-5,6-diacetyloxy-1',7',7'-trimethyl-7-(4-methylphenyl)sulfonyloxyspiro[3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole-2,2'-bicyclo[2.2.1]heptane]-4-yl] acetate
  参考文献：
  名称：

  Facile and practical synthesis of optically pure 1 d - chiro -inositol from myo -inositol

  摘要：

  Optically pure 1D-chiro-inositol (DCI) has been synthesized from optically inactive myo-inositol practically in four steps. The crystalline nature of most intermediates and the utilization of inexpensive reagents facilitate the economical mass production of DCI, which is expected to be used in the future for treatment of Type 2 diabetes and polycystic ovary syndrome (PCOS). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)02178-x
• 作为产物：
  描述：

  Inositol 在 吡啶 、 硫酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 40.0h， 生成 [(1'R,3aR,4S,4'R,5R,6S,7S,7aR)-5,6,7-trihydroxy-1',7',7'-trimethylspiro[3a,4,5,6,7,7a-hexahydro-1,3-benzodioxole-2,2'-bicyclo[2.2.1]heptane]-4-yl] 4-methylbenzenesulfonate
  参考文献：
  名称：

  Facile and practical synthesis of optically pure 1 d - chiro -inositol from myo -inositol

  摘要：

  Optically pure 1D-chiro-inositol (DCI) has been synthesized from optically inactive myo-inositol practically in four steps. The crystalline nature of most intermediates and the utilization of inexpensive reagents facilitate the economical mass production of DCI, which is expected to be used in the future for treatment of Type 2 diabetes and polycystic ovary syndrome (PCOS). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)02178-x